GlassScriptPhysician profile
Willard M West
NPI 1598718330
$341.06
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $94.35.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $68.18 | 2019 | |
| Abbvie INC. | $56.59 | 2019 | |
| Novo Nordisk INC | $52.46 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $41.56 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $22.57 | 2020 | |
| Allergan, INC. | $21.30 | 2020 | |
| Gilead Sciences, INC. | $19.78 | 2019 | |
| Boston Scientific Corporation | $18.81 | 2019 | |
| Merck Sharp & Dohme LLC | $14.98 | 2019 | |
| Celgene Corporation | $12.59 | 2019 | |
| Radius Health, INC. | $12.24 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willard West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.